Regenxbio announced that it intends to offer and sell, subject to market conditions, $125M of its common stock in an underwritten public offering. Morgan Stanley, Goldman Sachs & Co., Barclays and Stifel are acting as joint book-running managers of the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RGNX:
- Regenxbio’s RGX-202 shows initial efficacy in Duchenne
- REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
- Regenxbio expects cash to fund operations into 2H25
- Regenxbio reports Q4 EPS ($1.34), consensus ($1.27)
- RGNX Earnings this Week: How Will it Perform?
